• Spatially Concentrated ABEs Correct PLP1 Mutations in Oligod

  2026-05-21

  This study introduces a spatially concentrated adenine base editor (cABE) system that achieves efficient and precise correction of PLP1 point mutations in oligodendrocytes, a key advance for gene therapy of Pelizaeus–Merzbacher disease. By exploiting nuclear enrichment and phase-separation dynamics, the approach overcomes previous barriers in editing efficiency and off-target risk, offering a promising framework for treating hypomyelinating disorders.

• Ridaforolimus (Deforolimus): Applied Workflows in Cancer Res

  2026-05-21

  Ridaforolimus (Deforolimus, MK-8669) is redefining cancer and senescence research by enabling reliable mTOR pathway inhibition, robust antiproliferative assays, and anti-angiogenic workflows. This article synthesizes cutting-edge protocol design, troubleshooting, and translational application, bridging machine learning-driven senolytic discovery with practical benchtop execution.

• Cediranib (AZD2171) in Cancer Research: Applied Protocols &

  2026-05-20

  Cediranib (AZD2171) stands out as a potent and selective angiogenesis inhibitor for in vitro cancer research, offering precise modulation of VEGFR signaling with minimal cytotoxicity at nanomolar concentrations. This article delivers actionable guidance on experimental design, protocol optimization, and troubleshooting, ensuring reliable outcomes when interrogating tumor angiogenesis and signaling pathways.

• CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research

  2026-05-20

  CP-673451 enables precise interrogation of PDGFR-driven signaling and angiogenesis in cancer models, with unique advantages in ATRX-deficient glioblastoma research. This article demystifies the optimal experimental workflows, highlights troubleshooting strategies, and translates recent breakthroughs into actionable protocol enhancements.

• Tigecycline in Multidrug Resistance: Beyond Conventional Mod

  2026-05-19

  Explore the role of Tigecycline as a glycylcycline antibiotic in overcoming multidrug-resistant bacteria. This article uniquely analyzes transmission genetics and assay design, offering deeper scientific context for advanced microbiological research.

• Triiodothyronine (T3): Precision Tool for Thyroid Hormone Si

  2026-05-19

  Triiodothyronine (T3) is a core thyroid hormone that modulates metabolism, growth, and gene expression. High-purity T3 from APExBIO supports reproducible studies in thyroid hormone signaling pathways and metabolic disorder research. Its well-characterized biochemical properties make it the benchmark reagent for advanced cellular metabolism assays.

• Refining In Vitro Evaluation of Drug Responses in Cancer Res

  2026-05-18

  Schwartz’s dissertation introduces a dual-metric approach to in vitro anti-cancer drug testing, distinguishing proliferative arrest from cell death. This methodological advance clarifies drug action mechanisms and improves the rigor of preclinical cancer drug evaluation.

• Transcription Condensates Govern Histone Expression and Geno

  2026-05-18

  Marmolejo et al. reveal how the cell cycle regulates transcription condensates at histone locus bodies (HLBs) to coordinate linker histone gene expression with DNA replication. This balance, mediated by DDK, CDK1/2, and ATR-CHK1 kinases, is essential for genome stability and offers mechanistic insight relevant to cancer and cell cycle research.

• Light-Inducible RNA-Releasing Protein: Advances in Translati

  2026-05-17

  The referenced study introduces a rationally designed, light-inducible RNA-releasing protein (LIRP) that enables precise, light-dependent translational regulation in vivo. This innovation offers flexible, on-demand control of therapeutic gene expression, addressing key limitations in gene therapy for chronic and retinal diseases.

• BRCA2 Protects RAD51 Filaments from PARP Inhibitor-Induced D

  2026-05-16

  This study defines a mechanistic role for BRCA2 in safeguarding RAD51 filaments from destabilization caused by PARP inhibitor (PARPi)-induced PARP1 retention on DNA. These findings clarify why BRCA2-deficient tumors are selectively sensitive to PARPi, deepening the molecular understanding of homologous recombination deficient cancer treatment strategies.

• Cediranib (AZD2171): Strategic Insights for Translational Ca

  2026-05-15

  This thought-leadership article explores the mechanistic and translational impact of Cediranib (AZD2171), an ATP-competitive VEGFR tyrosine kinase inhibitor, in advanced cancer research. By integrating in vitro evaluation paradigms, evidence-based insights, and actionable protocol guidance, the article provides a strategic roadmap for researchers aiming to leverage Cediranib in angiogenesis and signaling pathway investigations. Building on recent scholarship and extending beyond conventional product narratives, the discussion situates Cediranib within the evolving landscape of translational oncology.

• Neomycin Sulfate: Precision Tool for RNA/DNA Structure Studi

  2026-05-15

  Neomycin sulfate stands apart as an aminoglycoside antibiotic uniquely leveraged for molecular biology research, especially in dissecting RNA/DNA interactions and probing ion channel function. This article details optimized workflows, advanced use-cases, and actionable troubleshooting strategies that maximize assay sensitivity and reproducibility using APExBIO's high-purity Neomycin sulfate.

• Cediranib (AZD2171) in Cancer Research: Applied Protocols &

  2026-05-14

  Cediranib (AZD2171) empowers cancer researchers with nanomolar potency and a broad kinase inhibition spectrum, uniquely enabling high-sensitivity analysis of angiogenesis and PI3K/Akt/mTOR signaling in vitro. This article delivers actionable protocol enhancements, troubleshooting insights, and a translational bridge to next-generation drug response evaluation workflows, leveraging the rigor of recent reference studies.

• Biotin (Vitamin B7): Precision in Protein Biotinylation Work

  2026-05-14

  APExBIO’s high-purity Biotin (Vitamin B7) empowers rigorous protein biotinylation and metabolic research through robust, reproducible workflows. Leverage biotin’s dual function as a coenzyme and biotin labeling reagent to enable high-sensitivity detection and advanced molecular assays.

• A Drug-Sensitized Yeast Platform for mTOR Inhibitor Discover

  2026-05-13

  This study introduces a highly sensitive yeast-based screening system for identifying mTOR inhibitors, dramatically improving detection limits compared to wild-type strains. The platform enables rapid, cost-effective evaluation of candidate molecules relevant to aging, cancer, and pharmacology research.

16308 records 1/1088 page Next 12345 下5页 Last page